A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.

Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...

Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...

Sales of PFE’s COVID Products Declining Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined steeply in 2023 due to lower demand following the end of the pandemic. In 2024 ...

Pfizer's third-quarter performance exceeded expectations, driven by a surge in demand for its COVID-19 treatment Paxlovid, ...

Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, are expected to have declined due to lower demand. Pfizer records direct sales and alliance revenues from its partner, BioNTech for the ...

Pfizer faces near-term challenges as COVID-19 product sales decline. However, excluding Comirnaty and Paxlovid, revenue grew 14% operationally in Q2 2024. This result demonstrates the strength of ...

Albert Bourla, who four years ago led Pfizer through its scientific and financial triumph during the covid-19 pandemic, is suddenly facing a new challenge from a large shareholder frustrated over ...

Pfizer's business rapidly expanded during the COVID-19 pandemic, thanks to a temporary growth spurt from selling Comirnaty (its COVID-19 vaccine) and Paxlovid (its antiviral therapy for COVID-19).

The durability of sales from Pfizer's COVID franchise, including vaccines and treatments like Paxlovid, is seen as a potential source of ongoing revenue, though more data could help solidify this ...